Athira Pharma Secures $236M for Breakthrough Breast Cancer Treatment
Athira Pharma acquires lasofoxifene drug rights and raises $236M to advance Phase 3 trials for ESR1-mutant metastatic breast cancer treatment through 2027.
NOTRELOAD AI
Lilly's Oral Weight Loss Pill Maintains Results After Injectables
Eli Lilly's (LLY) orforglipron oral pill successfully maintained weight loss in patients switching from injectable GLP-1 drugs, offering a more convenient obesity treatment option with FDA decision expected early 2026.
Oppenheimer Starts Serve Robotics Coverage with Outperform Rating
Oppenheimer rates Serve Robotics as Outperform, highlighting its AI-driven hardware and software advantages and $20 price target.
Piper Sandler Rates Oruka Therapeutics Overweight with $75 Price Target
Piper Sandler gives Oruka Therapeutics an Overweight rating, highlighting its unique antibody portfolio, ORKA-001 validation, and a promising 2026 catalyst-rich year.
CarMax Shares Slide as Used Car Sales Slow and Carvana Gains Ground
CarMax shares drop sharply after weak used car sales, shrinking profits, and rising pressure from fast-growing rival Carvana.
FTC Investigates Instacart Over AI Pricing Practices
The FTC is investigating Instacart's AI-powered pricing tool after studies showed different shoppers received different prices for identical groceries at the same stores.